Table 1.
Clinical characteristics of all included childhood Ph+ ALL patients
| Adherence (n=61) | Poor adherence (n=29) | p-value | |
|---|---|---|---|
| Male sex | 37 (60.6) | 20 (69.0) | 0.445 |
| Age (yr) | 9 (2–17) | 9 (3–16) | 0.199 |
| Parental education less than or equal to high school | 27 (44.3) | 11 (37.9) | 0.570 |
| Monthly family income (CNY) | |||
| < 2,000 | 18 (29.5) | 7 (24.1) | 0.805 |
| 2,000–5,000 | 14 (22.9) | 9 (31.0) | |
| > 5,000 | 11 (18.0) | 6 (20.7) | |
| Missing | 18 (29.5) | 7 (24.1) | |
| Forms of BCR/ABL oncogene | |||
| BCR/ABL P190 | 54 | 22 | 0.121 |
| BCR/ABL P210 | 7 | 7 | |
| MRD negative on day 19 | 29 (47.5) | 12 (41.4) | 0.583 |
| MRD negative on day 46 | 53 (86.9) | 25 (86.2) | 0.930 |
| Complex karyotype with t(9;22) | 20 (32.8) | 10 (34.5) | 0.873 |
| A normal karyotype (46,XX or 46,XY) | 14 (23.0) | 6 (20.7) | 0.809 |
| Concurrence of IKZF1 deletion | 18 (29.5) | 7 (24.1) | 0.283 |
| TKI switching during treatment | 15 (24.6) | 7 (24.1) | 0.963 |
| Duration of TKIs interruption (day) | 13 (0–101) | 56 (11–128) | < 0.001 |
| Dose reduction of TKIs | 14 (23.0) | 16 (55.2) | 0.002 |
| Current TKI therapy | |||
| Imatinib | 3 (4.9) | 6 (20.7) | 0.027 |
| Dasatinib | 49 (80.3) | 22 (75.9) | |
| Others | 9 (14.8) | 1 (3.4) | |
Permission for use of the scale and its coding is required. A license agreement is available from MMAR, LLC., www.moriskyscale.com. Values are presented as number (%) or median (range). ALL, acute lymphoblastic leukemia; CNY, Chinese Yuan RMB; MRD, minimal residual disease; Ph+, chromosome-positive; TKI, tyrosine kinase inhibitor.